In VivoPharmaceutical companies have a variety of strategic options available to them to restock pipelines and ensure continued innovation. In terms of external innovation, in-licensing assets from other com
In Vivo“I’m always keeping an eye on anything that’s going to the capital markets, whether that’s interest rates... a big change in the regulatory environment...anything that impacts capital markets and inve
ScripChina-originated, DLL3-targeting antibody-drug conjugates (ADCs) are arousing the interest of global partners at the start of the year, with both Innovent Biologics and Jiangsu Hengrui Medicine announ
ScripBiopharmaceutical companies remained on the hunt for cancer antibody-drug conjugate assets this summer, as deals revolving around ADCs accounted for five of 12 cancer-related deals, according to Biome